We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Stryker's (SYK) Latest Launch to Streamline Procedural Workflows
Read MoreHide Full Article
Stryker Corporation (SYK - Free Report) recently announced the release of its Gamma4 Hip Fracture Nailing System in most of its European markets. The system received the CE certification in Europe in September 2023.
The Gamma4 System, which has already been used in more than 25,000 cases in North America and Japan, is indicated for the treatment of fractures in the intracapsular, trochanteric, subtrochanteric and shaft regions of the femur (including osteoporotic and osteopenic bone).
The latest launch is likely to provide a significant boost to Stryker’s European Trauma & Extremities division and solidify its foothold in the niche space. Notably, the Trauma & Extremities division is part of its broader Orthopaedics and Spine segment.
Significance of the Launch
Per Stryker, the latest Gamma system is expected to provide surgeons with the next generation of the company’s intramedullary nailing system. The Gamma4 system is designed to treat hip and femur fractures and streamline procedural workflows for surgeons.
Management is optimistic about the latest development within the Gamma legacy, which has enabled it to expand availability to its European customers following a successful U.S. launch. Management believes that the latest system will likely aid its customers in rebuilding patient lives.
Industry Prospects
Per a report by Zion Market Research, the global orthopedic trauma devices market was worth around $18.5 billion in 2022 and is anticipated to reach $38.2 billion by 2030 at a CAGR of 9.5%. Factors like a growing elderly population, the rising prevalence of osteoporosis and musculoskeletal diseases, and the increasing incidence of sports and traumatic injuries are expected to drive the market.
Given the market potential, the latest launch is expected to boost Stryker’s business globally.
Recent Developments
This month, Stryker completed the acquisition of SERF SAS, a France-based joint replacement company from Menix. Together with the SERF SAS team, Stryker aims to aid in advanced product innovation and customer satisfaction.
Last month, Stryker announced the successful completion of the first shoulder arthroplasty surgeries using Blueprint Mixed Reality (MR) Guidance in Europe. The Blueprint MR Guidance System allows surgeons and their instruments to be guided by 3D images and guidance widgets, which can be displayed on the patient and in the surgeon’s line of sight without disrupting normal workflow.
In January, Stryker announced its fourth-quarter 2023 results, wherein it recorded a solid uptick in its top line and bottom line. Its Orthopaedics and Spine segment’s revenues were also strong, both on a reported and constant currency basis.
Price Performance
Shares of the company have gained 25.9% in the past year compared with the industry’s 5.5% rise and the S&P 500's 31% growth.
Image Source: Zacks Investment Research
Zacks Rank & Other Key Picks
Currently, Stryker carries a Zacks Rank #2 (Buy).
A few other top-ranked stocks in the broader medical space are DaVita Inc. (DVA - Free Report) , Cardinal Health, Inc. (CAH - Free Report) and Cencora, Inc. (COR - Free Report) .
DaVita, flaunting a Zacks Rank #1 at present (Strong Buy), has an estimated long-term growth rate of 12.1%. DVA’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 35.6%. You can see the complete list of today’s Zacks #1 Rank stocks here.
DaVita’s shares have gained 75.3% compared with the industry’s 21.8% rise in the past year.
Cardinal Health, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 14.2%. CAH’s earnings surpassed estimates in each of the trailing four quarters, with the average being 15.6%.
Cardinal Health has gained 56.7% compared with the industry’s 15.4% rise in the past year.
Cencora, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 9.8%. COR’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 6.7%.
Cencora’s shares have rallied 54.9% compared with the industry’s 5.8% rise in the past year.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Stryker's (SYK) Latest Launch to Streamline Procedural Workflows
Stryker Corporation (SYK - Free Report) recently announced the release of its Gamma4 Hip Fracture Nailing System in most of its European markets. The system received the CE certification in Europe in September 2023.
The Gamma4 System, which has already been used in more than 25,000 cases in North America and Japan, is indicated for the treatment of fractures in the intracapsular, trochanteric, subtrochanteric and shaft regions of the femur (including osteoporotic and osteopenic bone).
The latest launch is likely to provide a significant boost to Stryker’s European Trauma & Extremities division and solidify its foothold in the niche space. Notably, the Trauma & Extremities division is part of its broader Orthopaedics and Spine segment.
Significance of the Launch
Per Stryker, the latest Gamma system is expected to provide surgeons with the next generation of the company’s intramedullary nailing system. The Gamma4 system is designed to treat hip and femur fractures and streamline procedural workflows for surgeons.
Management is optimistic about the latest development within the Gamma legacy, which has enabled it to expand availability to its European customers following a successful U.S. launch. Management believes that the latest system will likely aid its customers in rebuilding patient lives.
Industry Prospects
Per a report by Zion Market Research, the global orthopedic trauma devices market was worth around $18.5 billion in 2022 and is anticipated to reach $38.2 billion by 2030 at a CAGR of 9.5%. Factors like a growing elderly population, the rising prevalence of osteoporosis and musculoskeletal diseases, and the increasing incidence of sports and traumatic injuries are expected to drive the market.
Given the market potential, the latest launch is expected to boost Stryker’s business globally.
Recent Developments
This month, Stryker completed the acquisition of SERF SAS, a France-based joint replacement company from Menix. Together with the SERF SAS team, Stryker aims to aid in advanced product innovation and customer satisfaction.
Last month, Stryker announced the successful completion of the first shoulder arthroplasty surgeries using Blueprint Mixed Reality (MR) Guidance in Europe. The Blueprint MR Guidance System allows surgeons and their instruments to be guided by 3D images and guidance widgets, which can be displayed on the patient and in the surgeon’s line of sight without disrupting normal workflow.
In January, Stryker announced its fourth-quarter 2023 results, wherein it recorded a solid uptick in its top line and bottom line. Its Orthopaedics and Spine segment’s revenues were also strong, both on a reported and constant currency basis.
Price Performance
Shares of the company have gained 25.9% in the past year compared with the industry’s 5.5% rise and the S&P 500's 31% growth.
Image Source: Zacks Investment Research
Zacks Rank & Other Key Picks
Currently, Stryker carries a Zacks Rank #2 (Buy).
A few other top-ranked stocks in the broader medical space are DaVita Inc. (DVA - Free Report) , Cardinal Health, Inc. (CAH - Free Report) and Cencora, Inc. (COR - Free Report) .
DaVita, flaunting a Zacks Rank #1 at present (Strong Buy), has an estimated long-term growth rate of 12.1%. DVA’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 35.6%. You can see the complete list of today’s Zacks #1 Rank stocks here.
DaVita’s shares have gained 75.3% compared with the industry’s 21.8% rise in the past year.
Cardinal Health, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 14.2%. CAH’s earnings surpassed estimates in each of the trailing four quarters, with the average being 15.6%.
Cardinal Health has gained 56.7% compared with the industry’s 15.4% rise in the past year.
Cencora, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 9.8%. COR’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 6.7%.
Cencora’s shares have rallied 54.9% compared with the industry’s 5.8% rise in the past year.